Xolair (omalizumab) is a brand-name subcutaneous injection that’s prescribed for hives, asthma, and other conditions. This article covers topics such as side effects, dosage, and how Xolair works.

Xolair has gained ... treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine treatment. The approved dose is 300 mg by subcutaneous ...

"Celltrion files XOLAIR biosimilar for chronic spontaneous urticaria BLA" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. Two weeks ago, the Food and Drug Administration approved Xolair (omalizumab ...

Xolair was originally approved for the treatment of moderate-to-severe persistent allergic asthma in certain patients. It’s since been approved for chronic spontaneous urticaria, or hives ...